Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 455-463

  Cummings, Jeffrey ^a   Hodgkinson, Cassandra ^a   Odedra, Rajesh ^b   Sini, Patrizia ^b   Heaton, Simon P ^b   Mundt, Kirsten E ^b   Ward, Tim H ^a   Wilkinson, Robert W ^b   Growcott, Jim ^b   Hughes, Andrew ^b   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADZ 1152; ANTIGEN; AURORA KINASE INHIBITOR; AZD 1152; M30 ANTIGEN; M65 ANTIGEN; PYRAZOLE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; M30 ENZYME LINKED IMMUNOSORBENT ASSAY; M65 ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; RAT; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; KERATIN-18; MALE; NEOPLASMS, EXPERIMENTAL; PHOSPHORIC ACID ESTERS; QUINAZOLINES; RATS; RATS, NUDE; TUMOR MARKERS, BIOLOGICAL;

EID: 41649101581     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2136     Document Type: Article

References (44)

1. Zerhouni E. Medicine. The NIH roadmap. Science 2003;302:63-72.
2. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-20.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
4. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7.
5. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41-6.
6. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 2006;15:1078-82.
7. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Cancer Rev 2005;5:845-56.
8. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
9. Dalton WS, Friend SH. Cancer biomarkers - an invitation to the table. Science 2006;312:1165-8.
10. Bast RC, Jr., Lilja H, Urban N, et al. Translational crossroads for biomarkers. Clin Cancer Res 2005;11:6103-8.
11. Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov 2006;5:897-902.
12. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-68.
13. Hagg M, Biven K, Ueno T, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002;20:253-9.
14. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
15. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mappingof a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999;187:567-72.
16. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004;297:11-26.
17. Cummings J, Ranson M, Lacasse E, et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2006;95:42-8.
18. Cummings J, Ward TH, Lacasse E, et al. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2005;92:532-8.
19. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003;39:769-74.
20. Demiray M, Ulukaya EE, Arslan M, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006;24:669-76.
21. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lungcancer and helpful to predict the survival. Lung Cancer 2007;56:399-404.
22. Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007;13:3198-206.
23. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducingapop tosis. Clin Cancer Res 2007;13:3682-8.
24. Mortlock AA, Foote KM, Heron NM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24.
25. Griffiths GJ, Dubrez L, Morgan CP, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999;144:903-14.
26. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.
27. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
28. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995;55:2116-21.
29. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17.
30. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining-tumor apoptosis and necrosis in patient serum usingcytok eratin 18 as a biomarker. Cancer Lett 2004;214:1-9.
31. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005;59 Suppl 2:S359-62.
32. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006;94:1592-8.
33. Weber K, Osborn M, Moll R, Wiklund B, Luning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984;3:2707-14.
34. Silen A, Wiklund B, Andersson EL, Nilsson S. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scand J Clin Lab Invest 1995;55:153-61.
35. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40.
36. Seregni E, Coli A, Mazzucca N. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S15-22.
37. Brattstrom D, Wagenius G, Sandstrom P, et al. Newly developed assay measuring cytokeratins 8, 18 and 19 in serum is correlated to survival and tumor volume in patients with esophageal carcinoma. Dis Esophagus 2005;18:298-303.
38. Einarsson R, Barak V. TPS: a cytokeratin serum tumour marker for effective therapy control of cancer patient with focus on breast cancer. J Clin Ligand Assay 1997;22:348-51.
39. Dohmoto K, Hojo S, Fujita J, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 2001;91:468-73.
40. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
41. Roth GA, Krenn C, Brunner M, et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope M30 in critically ill patients. Shock 2004;22:218-20.
42. 396) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem 2007;40:651-5.
43. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078-87.
44. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the pancaspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007;7:218-25.